Cipla's North America business revenue hits record high in Q1 at $250 million

Indian drug maker Cipla's North America's business revenue reached an all-time high of $250 million in the first quarter of the ongoing financial year, registering a year-on-year growth of 13 per cent, the company said in a stock exchange intimation on Friday.

The company's branded prescription business in India grew at 10 per cent. Cipla's overall one India growth was offset by softness in trade generics business due to distribution model change, it said in a press release. Cipla's South Africa revenue grew 19 per cent YoY in local currency terms.

Cipla's share prices spiked nearly 6 per cent following announcement of the results, while benchmark indices were trading with robust gains of around 1.7 per cent as of 3:25 pm.


"In Q1FY25, we recorded revenue growth of 7% over last year with EBITDA margin of 25.6% driven by mix and other operational efficiencies. Our One-India business continued on its growth trajectory during the quarter, led by Branded Prescription which grew at 10%," said Umang Vohra, MD & CEO, Cipla.

"Going ahead, focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front," he added.

Cipla's net profit grew 17.4 per cent YoY on a consolidated basis to Rs 1,178 crore in Q1 while its revenue increased 7 per cent YoY to Rs 6,694 crore.

Cipla's EBITDA saw an increase of 13.8 per cent YoY to Rs 1,716 crore. EBITDA margin rose 154 bps in Q1FY25 to 25.6 per cent, up from 24.1 per cent in Q1FY24.